Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml

Exclusion Criteria

• •Unwilling to sign informed consent;
• •Younger than 18 years old;
• •Ocular condition that are of safety concern and that can interfere with the study results;
• •Visual field defects with an MD value above -15dB on either eye on Humphrey (or the equivalent in Octopus) and/or threatening fixation
• •Contact lens wearer;
• •Closed/barely open anterior chamber angles or history of acute angle closure on either eye as assessed by gonioscopy;
• •Ocular surgery (other than glaucoma surgery) or argon laser trabeculoplasty within the past three months on either eye;
• •Glaucoma surgery within the past 6 months on either eye;
• •Ocular inflammation/infection occurring within three months prior to pre-trial visit on either eye;
• •Concomitant topical ocular medication that can interfere with study medication on either eye;
• •Known hypersensitivity to any component of the trial drug solutions;
• •Other abnormal condition or symptom preventing the patient from entering the trial, according to the Investigator's judgement;
• •Refractive surgery patients at any time;
• •Women who are pregnant, are of childbearing potential and are not using adequate contraception or are nursing;
• •Inability to adhere to treatment/visit plan;
• •Have participated in any other Interventional clinical trial (i.e., requiring informed consent) involving an investigational drug within one month prior to pre-trial visit.
• •History of COPD, asthma or heart failure